To the Editor: Vitiligo is an acquired chronic depigmentation disorder of the skin
resulting from selective destruction of melanocytes.[1] Although it is not a life-threatening
disease, it may lead to disfigurement and is associated with many other autoimmune
diseases. According to a recent international consensus conference, vitiligo can be
classified into two major forms: nonsegmental vitiligo (NSV) and segmental vitiligo
(SV, accounts for 5–16% of all vitiligo cases). NSV typically evolves over time, in
both distribution and extension patterns, including acrofacial, generalized, mucosal,
and facial vitiligo [Figure 1a and 1b]. SV is relatively rare and is characterized
by unilateral or banded distribution along the ganglion segment. SV usually has an
early onset and spreads rapidly in the affected dermatomal area, including single
SV, double SV, and the multi-SV [Figure 1c and 1d].[2]
Figure 1
Clinical features of patients with nonsegmental vitiligo (a and b) and segmental vitiligo
(c and d).
There is still controversy about the pathogenesis of vitiligo. At present, there are
several major hypotheses: autoimmune mechanisms, cytotoxic mechanisms, intrinsic defect,
oxidant-antioxidant mechanisms, and neural mechanisms.[3] In recent years, genetic
factors have been found to play an increasingly important role in the occurrence and
development of vitiligo. One study has shown that the rs3213758 locus in the retinitis
pigmentosa GTPase regulator-interacting protein 1-like (RPGRIP1L)gene might increase
the risk of vitiligo in a Korean population.[4] In addition, several mutations in
the RPGRIP1L gene were associated with various clinical phenotypes of nervous system
diseases.[5] However, the relationship between RPGRIP1L gene polymorphisms and susceptibility
to SV in the Chinese Han population has not been reported. Therefore, this case-control
study involving 121 Chinese Han patients with SV (SV group), 129 Chinese Han patients
with NSV (NSV group), and 133 Chinese Han healthy controls (control group) was conducted
to explore the association of single nucleotide polymorphism (SNP) of the RPGRIP1L
gene with SV susceptibility and clinical features in the Chinese Han population, then
providing further theoretical evidence for the neurological theory of SV.
The study was conducted in accordance with the Declaration of Helsinki and was approved
by the Clinical Ethics Committee of Tongji Hospital. Only Han Chinese subjects were
included to avoid genotype and allele frequency variations among ethnic groups. Patients
with SV and NSV were diagnosed by more than two experts in Tongji Hospital, and those
who had undergone related treatment in the preceding 6 months were excluded. Active
vitiligo was defined as the appearance of new lesions or the enlargement of existing
lesions in 3 months before the study. The healthy controls were excluded if they had
received blood transfusions in the last 6 months or if they had other autoimmune diseases
or other depigmentation disorders, such as piebaldism and albinism. A questionnaire
was provided for all subjects to obtain basic information. Three groups were matched
for age (P = 0.914), gender (P = 0.986) and ethnicity. The genotype frequency of healthy
controls was consistent with Hardy-Weinberg equilibrium (P = 0.170).
Genomic DNA was obtained from peripheral venous blood using an OMEGA D3392-02 E.Z.N.A.TM
Blood DNA Kit. The purity and concentration of the DNA were measured by an ultramicrospectrophotometer
nucleic acid-protein analyzer (MaestroNano, Maestrogen Inc., USA). The RPGRIP1L gene
polymorphism data were obtained from the literature and human genome databases, and
rs3213758 was selected as the SNP locus of this study. Mutation analysis of the allele
was performed using a custom-designed TaqMan-MGB SNP genotyping assay and TaqMan-MGB
Gene Expression MasterMix (Thermo Fisher Scientific, assay ID: C__25937352_10). After
the genotyping was completed, 10% of the samples of each group were randomly selected
to repeat the genotyping with polymerase chain reaction. The primer sequences were
as follows: forward 5’-CTGAGCAACACTTTCACCCAT-3’; and reverse 5’-CTGCCTTACCAGCCTTCG-3’.
The product length was 169 bp, and the genotyping results were completely consistent
with the TaqMan-MGB probe genotyping results.
Data were analyzed using SPSS version 24.0 software (SPSS Inc., Chicago, IL, USA).
Differences in the distributions of clinical features, alleles and genotypic frequencies
of RPGRIP1L polymorphisms among three groups were evaluated with the Chi-square test.
The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using univariate
and multivariate logistic regressions to determine the relationship between the gene
polymorphism and genetic susceptibility to SV and the relationship between genotype
and various factors, such as age and gender. The statistical significance was defined
as P < 0.05.
The results showed that the CC, CT, and TT genotype frequencies for RPGRIP1L rs3213758
were 59.5%, 28.9%, and 11.6% in the SV group; 46.5%, 43.4%, and 10.1% in the NSV group;
and 45.9%, 47.4%, and 6.8% in healthy controls, respectively. The C and T allele frequencies
for RPGRIP1L rs3213758 were 74.0% and 26.0% in the SV group; 68.2% and 31.8% in the
NSV group; and 69.5% and 30.5% in healthy controls, respectively. When the CC genotype
was used as the reference, these findings showed that the CT genotype could significantly
reduce the susceptibility to SV (SV vs. NSV: 28.9% vs. 43.4%, P = 0.032, OR = 0.556,
95% CI = 0.324–0.953; SV vs. HT: 28.9% vs. 47.4%, P = 0.006, OR = 0.471, 95% CI =
0.275–0.804). Meanwhile, the overdominant model also showed that the CT genotype could
significantly reduce the susceptibility to SV (SV vs. NSV: P = 0.017, OR = 0.531,
95% CI = 0.314–0.897; SV vs. controls: P = 0.003, OR = 0.452, 95% CI = 0.269–0.761).
Although there was no statistical association between the TT genotype and SV genetic
susceptibility, the recessive model showed that the TT genotype had a tendency to
increase the risk of SV (SV vs. NSV: OR = 1.168, 95% CI = 0.525–2.597; SV vs. controls:
OR = 1.803, 95% CI = 0.750–4.331). The dominant model showed that the frequency of
the combined CT + TT genotype was significantly lowered in the SV group, compared
with the NSV group and control group (SV vs. NSV: P = 0.040, OR = 0.592, 95% CI =
0.358–0.977; SV vs. controls: P = 0.030, OR = 0.577, 95% CI = 0.350–0.949). In addition,
there was no significant difference in the frequency of the T allele between SV group
and NSV group or control group (all P > 0.05). And there was no significant difference
in the frequency of each genotype and allele between NSV and control groups (P > 0.05).
To evaluate the effect of the RPGRIP1L gene polymorphism in specific populations,
the relationship between the RPGRIP1L gene polymorphism and genetic susceptibility
to SV in a specific population was analyzed. The results showed that when the CC genotype
was used as a reference, compared with the NSV and control groups, the CT genotype
frequency of RPGRIP1L rs3213758 locus in SV group was significantly different in the
following subgroups: male (SV vs. NSV: P = 0.021; SV vs. HT: P = 0.005) and age <20
years (SV vs. NSV: P = 0.018; SV vs. HT: P <0.001); moreover, the CT genotype significantly
decreased the susceptibility to SV in males (SV vs. NSV: OR = 0.418, 95% CI = 0.199–0.876;
SV vs. HT: OR = 0.345, 95% CI = 0.164–0.742) and age <20 years old (SV vs. NSV: OR
= 0.380, 95% CI = 0.170–0.846, SV vs. HT: OR = 0.217, 95% CI = 0.097–0.484). At the
same time, the overdominant model showed that the CT genotype reduced the susceptibility
to SV in the following subgroups: male (SV vs. NSV: P = 0.015, OR = 0.410, 95% CI
= 0.200–0.841; SV vs. HT: P = 0.001, OR = 0.305, 95% CI = 0.148–0.630) and age <20
years (SV vs. NSV: P = 0.030; OR = 0.427, 95% CI = 0.198–0.921; SV vs. HT: P = 0.000,
OR = 0.217, 95% CI = 0.100–0.472). In addition, the dominant model showed that combined
CT + TT genotype frequency in male (SV vs. NSV: P = 0.033, OR = 0.472, 95% CI = 0.237–0.940;
SV vs. HT: P = 0.035, OR = 0.477, 95% CI = 0.239–0.950) and age <20 years (SV vs.
NSV: P = 0.020, OR = 0.423, 95% CI = 0.205–0.872; SV vs. HT P = 0.001, OR = 0.292,
95% CI = 0.139–0.611) also had significant differences between SV group and NSV group
or control group. However, there was no significant difference in the frequency of
the TT genotype in the recessive model (P > 0.05). In population of male and age <20
years, there was no significant difference in the frequency of each genotype and allele
between NSV group and control group (P > 0.05). For population of female and age ≥20
years, there was no significant difference in the frequency of each genotype among
three groups (P > 0.05).
In a SV group-only study, we found that there was no significant difference in the
staging of the disease, the age of disease onset, and the area of skin lesions in
SV patients with different genotypes. However, for the duration of the disease, when
the 0–6-month duration was used as the reference, the rate of patients with the CT
genotype at 6–12 months duration was 4.343-time higher than that of the patients with
the CC genotype. There was no significant difference in the more than 12-month duration
among SV patients with any genotype.
Although the pathogenesis of vitiligo is still unclear, genetic factors are now recognized
as an important cause of vitiligo. A study showed that the A allele at the RPGRIP1L
rs3213758 locus might increase the susceptibility to vitiligo in the Korean population.
The RPGRIP1L gene is located on chromosome 16q12.2 and plays an important role in
promoting normal development of the cerebellum and maintaining normal renal function.
Several mutations in the RPGRIP1L gene are associated with various clinical phenotypes
of nervous system diseases, including developmental delays, ataxia, and abnormal eye
movement. These mutations could also lead to kidney disease, Joubert syndrome. The
localization of RPGRIP1L to the ciliary axoneme, basal bodies, and centrosome or cytoplasm
suggested a shuttling of RPGRIP1L between these different subcellular compartments.
A dynamic localization has been observed in other nephronophthisis-associated proteins
and might reflect a variability of function with the cell cycle. In addition, RPGRIP1L
was present diffusely through the cytoplasm during cell division.[6] The primary cilium
is essential for skin morphogenesis through regulating the Notch, Wnt, and hedgehog
signaling pathways disrupting the RPGRIL1 gene in mice that resulted in reduced proliferation
and differentiation of follicular keratinocytes.[7] Several possible mechanisms related
to RPGRIP1L gene mutation could help to understand correlation between such mutation
and vitiligo. One fact that RPGRIP1L regulating proteasomal activity indicated that
altered proteasomal components, immunosubunits for example, might influence the degradation
process of soluble proteins and the generation of antigenic peptides thus resulting
in disordered autoimmune, which might play a potential role in vitiligo. In addition,
RPGRIP1L gene is important for the proliferation and differentiation of keratinocytes
while keratinocytes are necessary for maintenance of melanocytes through producing
growth factors and cytokines. Hence, the mutation affects melanocytes function in
an indirect way. The diffuse cellular localization of RPGRIP1L gene suggested that
it is engaged into multifunction in different subcellular compartments indicating
that such mutation might act in various cellular functions including depigmenting
disorder.[8] The D1264N (rs3213758) mutation involved a change from aspartic acid
(Asp1264) to asparagine (Asn1264). This study demonstrated that the CT genotype of
the RPGRIP1L gene rs3213758 locus could significantly reduce the susceptibility to
SV in a Chinese Han population. Although there was no significant difference in the
frequency of the TT genotype among the three groups, there was an increased trend
of susceptibility to SV. However, the combined CT + TT genotype was significantly
lowered in the SV group, compared with the NSV and control groups. This finding might
be because the CT genotype had a stronger ability to reduce susceptibility to SV than
the TT genotype. There was no significant difference in the frequency of each genotype
and allele between NSV and control groups, which further proved that the CT genotype
was only the protective genotype of SV. This study also demonstrated that the CT genotype
of the RPGRIP1L gene rs3213758 locus could significantly reduce the susceptibility
to SV in males and subjects aged <20 years. These data indicated that the CT genotype
of RPGRIP1L was protective against SV in the Chinese Han population, especially males
and subjects aged <20 years. Since some mutations in the RPGRIP1L gene were associated
with multiple clinical phenotypes of neurological diseases, we could infer that neural
factors are related to the susceptibility to SV in the Chinese Han population. This
study provided further evidence for the neural hypothesis of the pathogenesis of SV
in the Chinese Han population. There was no significant difference in the staging
of the disease, onset age, and the area of lesions among SV patients with the three
genotypes. However, in terms of the 6–12 months duration of disease, the rate of patients
with the CT genotype was 4.343-time greater than that of patients with the CC genotype.
Therefore, CT might reduce the susceptibility to SV, but it could also prolong the
duration. In addition, the frequency of the T allele in the SV group was higher than
that in the NSV group or the control group, indicating that the T allele might increase
the risk of vitiligo in a Chinese Han population. A study with larger sample size
is needed to further elucidate the role of the RPGRIP1L gene polymorphism and neural
factors in the susceptibility to SV in the future.
Declaration of patient consent
The authors certify that they have obtained patient consent form. In the form, the
parents have given their consent for the patient's images and other clinical information
to be reported in the journal. They understand that the patient's name and initials
will not be published and due efforts will be made to conceal her identity, but anonymity
cannot be guaranteed.
Financial support and sponsorship
This work was supported by a grant from the National Natural Science Foundation of
China (No. 81773306).
Conflicts of interest
There are no conflicts of interest.